MarginsXMarginsX
Home › Markets › Health Care › QTTB

Q32 Bio Inc. (QTTB)

QTTB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$8.29
-4.82% on the day
Market cap
$248.1M
Micro cap
Revenue · 2025
$53.7M
Prior year not contiguous
Net income · 2025
$29.8M
55.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1661998/000119312526099339/0001193125-26-099339-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerQTTB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001661998
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$53.7M
Net income$29.8M
Operating income$16.9M
Net margin55.5%
Operating margin31.5%
Revenue growthNo prior-year revenue to compare
Cash$48.3M
Total assets$61.8M
P/E (computed)8.3×
P/S (computed)4.6×

Warning signs

Cash runway
173.6 months
$289.6M cash at September 30, 2026
Share count, 1 year
+143.2%
2025-11-01 to 2026-10-31 · +829.7% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
$14.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Liquidity and Going Concern In accordance with the Financial Accounting Standards Board ( FASB ) Accounting Standards Update ( ASU ) 2014-15, Disclosure of Uncertainties about an Entity's ability to Continue as a Going Concern (Subtopic 205-40) , the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a goi"
10-Q 2026-11-04
Cash and burn$289.6M cash; operating cash flow -$5.0M a quarter.Report 2026-09-30
Shares outstanding29,923,882 (2026-10-31); 12,304,352 a year earlier; 57,934,332 three years earlier. 3y figure adjusted for split (1-for-18 overall).Cover page 2026-10-31
Reverse splits, 3 years1; latest 1-for-18 on 2024-03-26Source 2024-03-26
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 5 424B5 takedowns, 5 at the marketLatest 2026-07-15
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $15.0M, sold $460K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$8.9M-$4.4M$289.6MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2026
2026-06-30
Not filed-$8.9M-$3.1M$106.3MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2026
2026-03-31
Not filed-$7.6M-$6.3M$50.8MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2025
2025-12-31
Not filed$57.7M-$6.2M$48.3MNo debt tags$53.7M10-K 2026-03-10
Q3 2025
2025-09-30
Not filed-$7.4M-$4.2M$49.0MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2025
2025-06-30
Not filed-$9.5M-$10.7M$54.8MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2025
2025-03-31
Not filed-$11.0M-$12.5M$65.5MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2024
2024-12-31
$0-$14.2M-$11.4M$78.0M$0$010-K 2026-03-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-07-28
Latest annual report10-K2026-03-10
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 594 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.8%
1 month+8.1%
3 months-43.3%
Year to date+162.3%
1 year+294.1%
From 52-week high-59.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
LFCRLifecore Biomedical Inc.$6.42-0.08%$243.2M
CAMPCAMP4 Therapeutics Corporation$3.86+1.58%$242.2M
RCKTRocket Pharmaceuticals Inc.$2.16-6.09%$241.2M
BIOABioAge Labs Inc.$5.22-5.95%$239.9M
FTHFaeth Therapeutics Inc.$9.28-7.48%$239.8M
ARCTArcturus Therapeutics Holdings Inc.$8.31-0.60%$239.5M
TTRXTurn Therapeutics Inc.$8.55-8.51%$261.4M
INOInovio Pharmaceuticals Inc.$1.40-2.10%$262.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier